Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma. - Powles T; Choueiri TK; Motzer RJ; Jonasch E; Pal S; Tannir NM; Signoretti S; Kaldate R; Scheffold C; Wang E; Aftab DT; Escudier B; et al. (BMC cancer, 2021)